Lytix Biopharma announces today the nomination of four new board members. The four are the Swedish citizens, PhD Marie-Louise Fjällskog and PhD Evelina Vågesjö, the Norwegian citizen Kjetil Hestdal and the US citizen Jayson Rieger. They will all supplement the present board.
“I’m very happy that we have been able to nominate four international capacities on cancer treatment. All of them have been key in international successes within commercialising of cancer medicines”, says Gert Munthe, chairman of the board.
Lytix Biopharma entered previous August a milestone licence agreement with the US based dermatology company Verrica Pharmaceuticals for Lytix’ lead candidate LTX-315 for skin cancer diseases. In January, Lytix announced that the U.S Food and Drug Administration (FDA) has approved the company’s IND application for LTX-315, an oncolytic molecule in development for various solid tumours. The board of directors has decided to apply for a listing of the company on Euronext Growth, simultaneously carrying out a capital increase.
The US based healthcare dedicated venture investment firm PBM Capital will be an anchor investor in the capital raise.
The nomination committee consisted of Lars Bakklund, Lise von Tangen-Jordan and Baldur Sveinbjørnsson.
The four nominated are
- Marie-Louise Fjällskog, MD, PhD
Senior Life Science Executive with long track-record within Clinical Research and business within Immunology and Oncology. Chief Medical Officer, Sensei Biotherapeutics, Boston, USA Board Member of Biovica International AB, Sweden. Dr. Associate professor (docent) in Oncology, affiliated to Uppsala University.
- Evelina Vågesjö, PhD and MBA
Co-founder and CEO of Ilya Pharma AB, a company developing next-generation immunotherapies based on cutting edge medical research in immunophysiology and applied microbiology. Received numerous awards within Science and Innovation, One of the winners of Innovators Under 35 Europe from MIT Technology Review 2019.
- Kjetil Hestdal, MD, PhD
More than 20 years of entrepreneurship bringing patented products from early stage to launches and commercialization as well as transforming company to R&D to commercial focused company. Has led listed companies with broad international investor relation activities – former CEO of Photocure
- Jayson Rieger, PhD and MBA
Jayson Rieger has about 15 years' experience in cross-functional scientific and business leadership roles spanning business, research operations, drug discovery and product development in the life science. He presently serves as Managing Partner in PBM Capital and supports new investment evaluation, deal sourcing and provides business and technical support for portfolio companies. Jayson obtained his Ph.D. from the University of Virginia in Chemistry, has an MBA from the Darden Business School and earned his B.A. from Rollins College.